Biomarker Signatures of the Sleep-pain Enigma
1 other identifier
observational
111
1 country
1
Brief Summary
This is an observational, prospective study that will leverage existing Standard of Care (SOC) patient reported outcomes (PRO) and Electronic Medical Record (EMR) data and collect additional Pain Rating Scale (PRS) data and blood samples from patients who consent to be in the study. Active duty service members and DEERS eligible patients who are injured and/or will undergo elective orthopaedic surgery are the target population.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 10, 2018
CompletedStudy Start
First participant enrolled
February 2, 2019
CompletedFirst Posted
Study publicly available on registry
February 22, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 20, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
March 20, 2024
CompletedJanuary 28, 2026
May 1, 2024
5.1 years
December 10, 2018
January 26, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Biomarker Expression
To determine the biomarkers (microRNA, mRNA, proinflammatory cytokines) associated with the presence (risk-related) or absence (resilience related) of sleep dysregulation and pain prior to surgery. To determine the biomarkers associated with increases/maintenance (risk-related) and decreases (resilience-related) of sleep dysregulation and pain chronification after surgery. Protein Biomarker Analysis: The cytokine expression analysis will be done using the Human Inflammatory Cytokines Multi-Analyte ELISArray Kit. The cytokines and chemokines to be tested with this array include IL1α, IL1β, IL2, IL4, IL6, IL8, IL10, IL12, IL17A, IFNγ, TNFα, and GM-CSF (Qiagen Inc.). For this analysis, we will use 50ul of serum samples along with the 50ul of assay buffer which will be loaded in the ELISA strips.
Up to six months after surgery
Eligibility Criteria
Active duty service members and DEERS eligible patients who are injured and/or will undergo elective orthopedic surgery. Up to 240 patients will be enrolled in this study at Walter Reed National Military Medical Center
You may qualify if:
- Active duty military or DEERS eligible individuals
- Between the ages of 18 and 60 years old
- Able to understand written and spoken English
- Eligible for healthcare within Military Health Systems
- Having an orthopedic procedure at WRNMMC
You may not qualify if:
- Bleeding Disorder
- History of vasovagal response
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Walter Reed National Military Medical Center
Bethesda, Maryland, 20889, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Chester C Buckenmaier, III, MD
Defense and Veterans Center for Integrative Pain Management
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Research Nurse Manager
Study Record Dates
First Submitted
December 10, 2018
First Posted
February 22, 2019
Study Start
February 2, 2019
Primary Completion
March 20, 2024
Study Completion
March 20, 2024
Last Updated
January 28, 2026
Record last verified: 2024-05
Data Sharing
- IPD Sharing
- Will not share